Re-evaluating design of an initiated trial

Identifying the best overall strategy for study designs and drug development pathways

Re-evaluating design of an initiated trial

Re-evaluating design of an initiated trial 558 344 Exploristics

KerusCloud Use Example
De-risking once a study has initiated, adapting to new information

Re-evaluating the probability of success (PoS)
KerusCloud is a revolutionary simulation-guided study design tool that ensures clinical trials are designed effectively to collect the right data, in the right patients, in the right way. Its use supports evidence-based design decisions to extensively de-risk real clinical studies, reducing development time, costs and patient burden.
The Challenge

A sponsor biopharmaceutical company was running a clinical trial to examine the effect on an inflammatory biomarker of interest in patients treated with an investigative treatment versus placebo. Following initiation of the trial, two things changed:

Re-evaluating design of an initiated trial

Considering these changing circumstances, the sponsor wished to re-evaluate the probability of success (PoS) for the study if it was adapted to include fewer patients than initially planned.

The Approach

Exploristics carried out additional literature searches to obtain relevant background information on the clinical biomarker of interest to inform the strategy for the simulation work. This identified two critical design assumptions that were not considered at the initial design stage:

Re-evaluating design of an initiated trial
Re-evaluating design of an initiated trial

KerusCloud study simulation software was used to quantify the Probability of Success (PoS), going beyond the original sample size calculations to simultaneously evaluate multiple design and efficacy ‘what if’ scenarios. KerusCloud simulates patient level data and so was able to create virtual patient populations which could reflect the real-life data we would collect in the study, for example the truncation of biomarker data. The following scenarios were considered:

  • a range of assumed expected effect sizes (including larger than originally planned)
  • a range of assumed correlations between baseline and post dose (given the true underlying value was unknown)
  • different recruitment design decisions between 60% and 100% of the planned sample size
The Results

KerusCloud was used to rapidly quantify the PoS for these scenarios and then visualise in an interactive heatmap (Figure 1).

The PoS heatmap identified a previously hidden risk; the importance of the baseline to post dose correlation.

Simulated scenarios indicated that this correlation was a key driver of success and the study as originally planned was underpowered if the correlation was below 0.9.

The risk associated was quantified and the team could plan to mitigate this; by examining the correlation between baseline and post dose in a blinded fashion to provide key information for planning.

Re-evaluating design of an initiated trial
Figure 1. A KerusCloud heatmap showing the PoS values for different study scenarios, where dark blue indicates very low PoS and dark red indicates very high PoS.
The Impact

Simulation with KerusCloud provided key insights for the team when making decisions around the required sample size to support the design of this clinical trial, highlighting the benefits of simulation to fully explore the risks for a study.

  • Its use identified the importance of the baseline to post dose correlation in this study, enabling mitigation for this risk to be put in place through a blinded ongoing review of the data.
  • KerusCloud identified a viable design with an improved recruitment/risk profile relative to the original sample size calculation.
  • These insights gave the company a more flexible recruitment strategy, de-risking the study while saving time and costs.

Let’s talk!

If you’d like to discuss this use case example further or learn more on how our technology enabled services can support your development project, please contact our VP of Sales & Marketing, Abbas Shivji, at or book a call.